NCT00700206
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            May 2008
                                            Phase 2
                                                                                                                                                                                                            NCT00280631
                                            Telik
                                            Myelodysplastic Syndrome (MDS)
                                            February 2006
                                            Phase 1-Phase 2
                                                                                                                                                                                                            NCT00035867
                                            Telik
                                            Myelodysplastic Syndromes
                                            April 2002
                                            Phase 1-Phase 2
                                                                                                                                                                                                                                        View MoreCollapse                                                                                               
                                                                                        References
[1]. Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20.

 

"目录号: HY-13634A metabolic Enzyme/Protease            -                Ezatiostat 是一种 glutathione 类似物，为谷胱甘肽 S-转移酶 P1-1 (GSTP1-1) 抑制剂。 Gutathione S-transferase 相关产品 Ezatiostat hydrochloride  -   生物活性 Description Ezatiostat is a glutathione analog inhibitor of glutathione S-transferase P1-1 (GSTP1-1).                                                                                                                                                                                 In Vitro Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone[1].                                                                                                                                                                                 Clinical Trial                                                                                                                                                                                                                                                                                                            NCT01422486                                             Telik                                             Myelodysplastic Syndrome (MDS)                                             October 2011                                             Phase 2                                                                                                                                                                                                             NCT01459159                                             Telik                                             Myelodysplastic Syndrome (MDS)                                             October 2011                                             Phase 2                                                                                                                                                                                                             NCT00909584                                             Telik                                             Severe Chronic Neutropenia                                             April 2009                                             Phase 2                                                                                                                                                                                                             NCT01062152                                             Telik                                             Myelodysplastic Syndrome                                             November 2009                                             Phase 1                                                                                                                                                                                                             NCT00701870                                             Telik                                             Non-small Cell Lung Cancer                                             October 2008                                             Phase 2